GATA1 mutations in Down Syndrome: Implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia
- 1 January 2004
- journal article
- review article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 44 (1) , 40-44
- https://doi.org/10.1002/pbc.20066
Abstract
Although physicians have known for many decades that children with Down syndrome are predisposed to developing transient myeloproliferative disorder (TMD) and acute megakaryoblastic leukemia (AMKL), many questions regarding these disorders remain unresolved. First, what is the relationship between TMD and AMKL? Second, what specific genetic alterations contribute to the leukemic process? Finally, what factors lead to the increased predisposition to these myeloid disorders? In this review I will summarize important new insights into the biology of TMD and AMKL gained from the recent discovery that GATA1, a gene that encodes an essential hematopoietic transcription factor, is mutated in the leukemic blasts from nearly all patients with these malignancies. In addition, I will discuss whether assaying for the presence of a GATA1 mutation can aid in the diagnosis of these and related megakaryoblastic leukemias. Future research aimed at defining the activity of mutant GATA‐1 protein and identifying interacting factors encoded by chromosome 21 will likely lead to an even greater understanding of this intriguing leukemia.Keywords
This publication has 30 references indexed in Scilit:
- Recent insights into the mechanisms of myeloid leukemogenesis in Down syndromeBlood, 2004
- Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndromeBlood, 2003
- GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndromeBlood, 2003
- Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesisBlood, 2003
- Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorderPublished by Elsevier ,2003
- Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21Blood, 2003
- Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndromeNature Genetics, 2002
- The Management of Neoplastic Disorders of Haematopoeisis in Children with Down's SyndromeBritish Journal of Haematology, 2000
- A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet developmentThe EMBO Journal, 1997
- Alternative translation initiation site usage results in two functionally distinct forms of the GATA-1 transcription factor.Proceedings of the National Academy of Sciences, 1995